EGFR and lung adenocarcinoma: Furthermore, JAK2 inhibition can sensitize resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors, which suggests the potential utilities of JAK inhibitors toward the treatment of EGFR-TKI-resistant NSCLC (Gao et al., 2016).